Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events

被引:70
作者
Miller, Tamara P. [1 ,2 ]
Fisher, Brian T. [3 ,4 ,5 ,6 ]
Getz, Kelly D. [4 ,6 ,7 ]
Sack, Leah [7 ]
Razzaghi, Hanieh [7 ,8 ]
Seif, Alix E. [5 ,7 ]
Bagatell, Rochelle [5 ,7 ]
Adamson, Peter C. [5 ,7 ]
Aplenc, Richard [4 ,5 ,6 ,7 ,8 ]
机构
[1] Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, HSRB W-353,1760 Haygood Dr NE, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA
[3] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA
[4] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA
[5] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA
[6] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[7] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA
[8] Childrens Hosp Philadelphia, Dept Biomed & Hlth Informat, Philadelphia, PA 19104 USA
关键词
adverse events; clinical trials; pediatric oncology; ACUTE MYELOID-LEUKEMIA; CLINICAL-TRIAL; ONCOLOGY GROUP; PATIENT; ACCURACY; RISK;
D O I
10.1002/pbc.27747
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Adverse events (AEs) on Children's Oncology Group (COG) trials are reported manually by clinical research assistants (CRAs). The Common Terminology Criteria for Adverse Events (CTCAE) was developed to provide standardized definitions for identifying and grading AEs. The CTCAE has expanded significantly over its five versions, but the impact of CTCAE definitional changes has not been examined. Procedure This study compared AE number and ascertainment among the first four CTCAE versions using a case vignette. Each CTCAE version was used to create a list of AEs and grades by two separate CRAs. Results The CTCAE expanded from 9 categories and 49 AEs in v1.0 to 26 categories and 790 AEs in v4.0. CRAs independently selected different approaches to AE ascertainment-comprehensive and parsimonious. The number of AEs identified in the parsimonious approach was stable with 10-14 in each CTC version. The comprehensive approach identified 9, 20, 29, and 37 AEs in CTC versions 1.0, 2.0, 3.0, and 4.0, respectively. Only approximately 65% of AEs were conclusively graded in versions 2.0 to 4.0 using the comprehensive approach. Conclusions CTCAE has increased in complexity. Although this increased complexity allows for more granular AE reporting, these data demonstrate potential unintended negative consequences of increasing CTC AE complexity, including the risk of varying approaches to AE capture. A comprehensive evaluation of CTC AE definitions and CRA reporting practices across COG institutions and AEs are needed to improve the accuracy and efficiency of AE reporting.
引用
收藏
页数:7
相关论文
共 29 条
[1]  
[Anonymous], 2019, CHILDR ONC GROUP MEM
[2]  
[Anonymous], RESP ADV EV AE REP F
[3]  
[Anonymous], STAT INV FDA 1572
[4]   Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group [J].
Aplenc, R. ;
Fisher, B. T. ;
Huang, Y. S. ;
Li, Y. ;
Alonzo, T. A. ;
Gerbing, R. B. ;
Hall, M. ;
Bertoch, D. ;
Keren, R. ;
Seif, A. E. ;
Sung, L. ;
Adamson, P. C. ;
Gamis, A. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 :37-43
[5]   Patient online self-reporting of toxicity symptoms during chemotherapy [J].
Basch, E ;
Artz, D ;
Dulko, D ;
Scher, K ;
Sabbatini, P ;
Hensley, M ;
Mitra, N ;
Speakman, J ;
McCabe, M ;
Schrag, D .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3552-3561
[6]   Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study [J].
Basch, Ethan ;
Iasonos, Alexia ;
McDonough, Tiffani ;
Barz, Allison ;
Culkin, Ann ;
Kris, Mark G. ;
Scher, Howard I. ;
Schrag, Deborah .
LANCET ONCOLOGY, 2006, 7 (11) :903-909
[7]   Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0 [J].
Chen, Alice P. ;
Setser, Ann ;
Anadkat, Milan J. ;
Cotliar, Jonathan ;
Olsen, Elise A. ;
Garden, Benjamin C. ;
Lacouture, Mario E. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (05) :1025-1039
[8]   Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531 [J].
Gamis, Alan S. ;
Alonzo, Todd A. ;
Meshinchi, Soheil ;
Sung, Lillian ;
Gerbing, Robert B. ;
Raimondi, Susana C. ;
Hirsch, Betsy A. ;
Kahwash, Samir B. ;
Heerema-McKenney, Amy ;
Winter, Laura ;
Glick, Kathleen ;
Davies, Stella M. ;
Byron, Patti ;
Smith, Franklin O. ;
Aplenc, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3021-+
[9]   Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia [J].
Grupp, Stephan A. ;
Kalos, Michael ;
Barrett, David ;
Aplenc, Richard ;
Porter, David L. ;
Rheingold, Susan R. ;
Teachey, David T. ;
Chew, Anne ;
Hauck, Bernd ;
Wright, J. Fraser ;
Milone, Michael C. ;
Levine, Bruce L. ;
June, Carl H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (16) :1509-1518
[10]  
Gwede Clement K, 2002, J Oncol Manag, V11, P15